PDF herunterladen
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0043-1766128
Case Report with Review of Literature

Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature

Autoren

  • Bhavika Kothari

    1   Department of Breast Oncosurgery, Tata Memorial Centre, Mumbai, Maharashtra, India

  • Pallavi Parab

    2   Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

  • Seema Gulia

    2   Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

  • Sushmita Rath

    2   Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

  • Sudeep Gupta 

    2   Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

Funding None.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved in combination with endocrine-based therapy for the treatment of hormone receptor-positive (HR + )/human epidermal growth factor receptor 2-negative (HER2 − ) advanced or metastatic breast cancer. It can significantly prolong the progression-free survival and improve the objective response rate compared with hormone therapy alone. However, the combined regimen results in a higher risk of adverse events, one of them being dermatological reactions. We present a case of late severe skin toxicity in a patient who had received ribociclib for 5 months. The toxicity led to severe pruritus and maculopapular and patchy rash on upper and lower extremities, which completely resolved 1 month after cessation of the drug. We conclude that ribociclib-induced skin toxicity is a noteworthy side effect that can lead to permanent cessation of this drug and is reversible. There are clinical decision dilemmas related to continuation, withholding, or switching CDK4/6 inhibitors, and benefits should be weighed against toxicities and costs.

Keywords

metastatic breast cancer - ribociclib - skin toxicity - CDK4/6 inhibitors

Declaration of Patient Consent

The patient has provided written informed consent for the publication of this case report including clinical pictures, without including any patient identification.




Publikationsverlauf

Artikel online veröffentlicht:
17. April 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India